Privacy Policy

Login

Inställningar

Split view

Short keys for navigating in split view

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Dark Mode

Set dark mode to MFN.se

Sound

Plays a notification sound when new press release is published in the current feed

Söndag 22 December | 02:26:06 Europe / Stockholm

Svenska | English

Investor Relations

Public Relations

Redeye

Bifogade filer

Elicera Therapeutics Q3 - CARMA study on the way

Prenumeration

Elicera Therapeutics Q3 - CARMA study on the way

2024-11-29 13:26:00

Redeye returns following Elicera's Q3 report and recent news in the company. We largely reiterate our stance and see an exciting news flow ahead, most notably related to the ongoing studies with ELC-301 and ELC-100.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Redeye

Bifogade filer

Prenumeration

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden